Cornely, O.A., Arikan-Akdagli, S., Dannaoui, E., Groll, A.H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., Arendrup, M.C., Boekhout, T., Chowdhary, A., Cuenca-Estrella, M., Freiberger, T., Guinea, J., Guarro, J., de Hoog, S., Hope, W., Johnson, E., Kathuria, S., Lackner, M., Lass-Florl, C., Lortholary, O., Meis, J.F., Meletiadis, J., Munoz, P., Richardson, M., Roilides, E., Tortorano, A.M., Ullmann, A.J., van Diepeningen, A., Verweij, P. and Petrikkos, G. (2014) ESCMID and ECMM Joint Clinical Guidelines for the Diagnosis and Management of Mucormycosis 2013. Clinical Microbiology and Infection, 3, 5-26.
https://doi.org/10.1111/1469-0691.12371

has been cited by the following article:

• TITLE: Pharmacokinetic/Pharmacodynamic Analysis the Probability of Target Attainment of Posaconazole against Mucorales Species in Patients with Mucormycosis

  AUTHORS: Ying Wang, Jingyi Zhao, Yinhui Yao, Junhui Hu, Jiuli Hu, Xu Xiao, Yanwu Zhao

  KEYWORDS: Mote Carlo Simulation, Posaconazole, Mucorales, Mucormycosis

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.11 No.5, May 15, 2020

  ABSTRACT: The objective of this study was to investigate the probability of target attainment of various posaconazole dosing regimens against Mucorales species in patients with mucormycosis. According to pharmacokinetic/pharmacodynamic parameters of posaconazole in adults, the dosage regimen of posaconazole for mucormycosis included 50, 100, 200 and 400 mg orally q12h. Monte Carlo Simulation analysed the published parameters of pharmacokinetics and the MIC values of mucormycosis in Mucorales species. The results showed that posaconazole did not affect Rhizopus arrhizus and Mucor sp. The optimal dosage of posaconazole for Rhizopus microsporus and Rhizomucor pusillus was 400 mg orally q12h and the best dosage regimen for Lichtheimia corymbifera was 200 mg orally q12h. The antifungal activity of posaconazole against mucormycosis was different, and the dosage regimen needs to adjust according to fungal species.